Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 185 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers MOST POPULAR Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows December 13, 2018 Free Rides to Screening Appointments Thanks to Woman Who Lost Mother... May 16, 2019 Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive... July 2, 2025 The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer... September 20, 2021 Load more HOT NEWS Cancer in My Community: Obstacles to Caring for People With Cancer... Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR...
